You are currently viewing the summary.
See the full text- Join / Subscribe
- Buy article
- member account Enable
- Renew subscription
- Recommend a subscription to your library
- Help for librarians
Summary
The California Institute for Regenerative Medicine (CIRM) is at a key moment. During the last decade, he spent much of its $ 3 billion budget nourishing therapies of incipient disease, including 23 that have reached clinical trials. But many of his projects will not be ready to test in humans at the time of its state funding runs out. Last month, the board of CIRM approved an ambitious plan for 5 years to award the last of its funds in the next 5 years and to attract companies and pharmaceutical investors that could carry these projects forward his absence. But the leadership of the agency is also eyeing new sources of funding to keep it afloat after 2020.
0 Komentar